Johnson & Johnson (JNJ) Rating Lowered to Hold at Vetr

Vetr downgraded shares of Johnson & Johnson (NYSE:JNJ) from a buy rating to a hold rating in a report published on Monday morning. Vetr currently has $147.40 target price on the stock.

Other analysts also recently issued reports about the company. UBS Group reiterated a buy rating and set a $148.00 price target on shares of Johnson & Johnson in a report on Saturday, September 30th. Jefferies Group increased their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a buy rating in a report on Monday, October 16th. Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a buy rating in a report on Friday, October 6th. Citigroup increased their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a buy rating in a report on Monday, October 23rd. Finally, Barclays increased their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an equal weight rating in a research report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $145.52.

Shares of Johnson & Johnson (NYSE JNJ) traded up $0.82 during trading on Monday, reaching $144.79. The company’s stock had a trading volume of 4,962,045 shares, compared to its average volume of 5,920,000. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $145.68. The firm has a market cap of $388,980.00, a P/E ratio of 25.14, a P/E/G ratio of 2.67 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period last year, the business posted $1.68 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.32%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Several hedge funds have recently added to or reduced their stakes in the company. Acropolis Investment Management LLC lifted its position in Johnson & Johnson by 26.3% in the 4th quarter. Acropolis Investment Management LLC now owns 24,383 shares of the company’s stock valued at $3,407,000 after acquiring an additional 5,080 shares in the last quarter. Sawyer & Company Inc bought a new position in Johnson & Johnson in the 4th quarter valued at about $3,726,000. American National Bank lifted its position in Johnson & Johnson by 6.0% in the 4th quarter. American National Bank now owns 58,898 shares of the company’s stock valued at $8,230,000 after acquiring an additional 3,309 shares in the last quarter. Stock Yards Bank & Trust Co. lifted its position in Johnson & Johnson by 13.7% in the 4th quarter. Stock Yards Bank & Trust Co. now owns 153,470 shares of the company’s stock valued at $21,442,000 after acquiring an additional 18,540 shares in the last quarter. Finally, Windward Capital Management Co. CA lifted its position in Johnson & Johnson by 3.0% in the 4th quarter. Windward Capital Management Co. CA now owns 93,768 shares of the company’s stock valued at $13,101,000 after acquiring an additional 2,755 shares in the last quarter. 65.70% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.themarketsdaily.com/2018/01/12/johnson-johnson-jnj-rating-lowered-to-hold-at-vetr-2.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply